AI could help GPs catch hidden liver disease before It's too late
NCT ID NCT07305324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether an AI tool called FibroX can help primary care providers better diagnose advanced liver fibrosis in people with MASLD, a common liver condition. Forty providers will review simulated patient cases, using either standard methods or FibroX, which gives a risk score and explanation. The goal is to see if the AI improves diagnostic accuracy, trust, and ease of use, potentially leading to earlier detection and better care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FibroX (AI software tool)
What this could lead to
If successful, this AI tool could help primary care doctors catch liver scarring earlier and more accurately, potentially reducing unnecessary referrals and missed diagnoses.
What could go wrong
This is a small pilot study with only 40 providers using simulated cases, not real patients. The AI may not work as well in real-world clinics or with diverse populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••